Trichosporon beigelii, an emerging pathogen resistant to amphotericin B.

PubWeight™: 2.99‹?› | Rank: Top 1%

🔗 View Article (PMC 267999)

Published in J Clin Microbiol on July 01, 1990

Authors

T J Walsh1, G P Melcher, M G Rinaldi, J Lecciones, D A McGough, P Kelly, J Lee, D Callender, M Rubin, P A Pizzo

Author Affiliations

1: Infectious Diseases Section, National Cancer Institute, Bethesda, Maryland 20892.

Articles citing this

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76

Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04

Epidemiology of nosocomial fungal infections. Clin Microbiol Rev (1996) 5.03

New and emerging yeast pathogens. Clin Microbiol Rev (1995) 4.75

Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol (2004) 4.03

Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03

Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82

Fungal infections: a growing threat. Public Health Rep (1996) 2.59

Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol (2005) 2.45

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol (2001) 2.13

Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev (2011) 2.08

Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04

In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother (2002) 2.03

Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother (2005) 1.92

Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90

Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72

In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis (1998) 1.71

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother (2000) 1.59

Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol (2001) 1.52

Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother (2004) 1.50

Emerging pan-resistance in Trichosporon species: a case report. BMC Infect Dis (2016) 1.45

Fungal infections in primary immunodeficiencies. Eur J Pediatr (2007) 1.37

Trichosporon loubieri infection in a patient with adult polycystic kidney disease. J Clin Microbiol (2003) 1.15

Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol (2009) 1.14

Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother (1994) 1.13

Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother (2005) 1.05

Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02

Disseminated trichosporonosis caused by Trichosporon loubieri. J Clin Microbiol (2003) 1.00

PCR detection of DNA specific for Trichosporon species in serum of patients with disseminated trichosporonosis. J Clin Microbiol (1999) 0.95

Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism. J Clin Microbiol (2004) 0.94

Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii. Antimicrob Agents Chemother (2013) 0.93

In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother (2004) 0.87

A novel murine model of disseminated trichosporonosis. Infect Immun (1992) 0.87

Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis. Infect Immun (1997) 0.86

Disseminated hyalohyphomycosis caused by a novel human pathogen, Fusarium napiforme. J Clin Microbiol (1993) 0.86

Fatal disseminated Trichosporon asahii infection in a child with acute lymphoblastic leukemia. Can J Infect Dis Med Microbiol (2008) 0.85

Genetic diversity and antifungal susceptibility testing of Trichosporon asahii isolated of Intensive Care Units patients. Braz J Microbiol (2008) 0.85

Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014. Open Forum Infect Dis (2015) 0.84

Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother (2006) 0.84

Antifungals: need to search for a new molecular target. Indian J Pharm Sci (2010) 0.84

Disseminated Trichosporon beigelii infection in an immunosuppressed child. J R Soc Med (1994) 0.83

Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Antimicrob Agents Chemother (1995) 0.82

Two Case Presentations Infected by Trichosporon asahii and Treated with Voriconazole Successfully. Case Rep Infect Dis (2015) 0.82

A Rare Case of Nosocomial Urinary Tract Infection due to Trichosporon asahii. J Glob Infect Dis (2011) 0.81

Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen. Front Microbiol (2016) 0.79

Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes against Trichosporon asahii. Clin Exp Immunol (2000) 0.78

Trichosporon asahii urinary tract infection in immunocompetent patients. Med J Armed Forces India (2014) 0.78

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77

In Vitro Interactions between Non-Steroidal Anti-Inflammatory Drugs and Antifungal Agents against Planktonic and Biofilm Forms of Trichosporon asahii. PLoS One (2016) 0.77

Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2005) 0.75

A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats. AAPS PharmSciTech (2015) 0.75

Emerging Trichosporon asahii in elderly patients: epidemiological and molecular analysis by the DiversiLab system. Eur J Clin Microbiol Infect Dis (2014) 0.75

Articles cited by this

Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol (1984) 2.99

Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol (1989) 2.63

Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol (1985) 2.53

Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44

Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15

Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) (1986) 2.11

Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci (1979) 2.02

Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol (1977) 1.94

Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med (1985) 1.84

Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis (1983) 1.69

Trichosporonosis. Infect Dis Clin North Am (1989) 1.54

Disseminated infection with Trichosporon beigelii. Rev Infect Dis (1988) 1.40

Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol (1987) 1.37

Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis (1988) 1.36

Demonstration, by immunoelectronmicroscopy, of a cell wall antigen in Trichosporon beigelii that cross-reacts with Cryptococcus neoformans capsular polysaccharide. J Infect Dis (1988) 1.13

Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. J Infect Dis (1983) 1.13

Articles by these authors

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis (1997) 14.49

The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc (1999) 14.47

Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13

Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science (2001) 11.56

Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96

Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04

Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04

Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol (1988) 8.67

Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42

Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana. Nature (1999) 8.04

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49

Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33

Guided medication dosing for inpatients with renal insufficiency. JAMA (2001) 6.25

Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02

The earliest angiosperms: evidence from mitochondrial, plastid and nuclear genomes. Nature (1999) 5.85

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64

Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32

Odds ratio or relative risk for cross-sectional data? Int J Epidemiol (1994) 5.27

Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science (1994) 5.20

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98

A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84

Prevention of fat-induced insulin resistance by salicylate. J Clin Invest (2001) 4.74

Structure and functional expression of a human interleukin-8 receptor. Science (1991) 4.74

Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49

Estimation of prevalence rate ratios for cross sectional data: an example in occupational epidemiology. Br J Ind Med (1993) 4.41

Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27

Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23

Identification of heregulin, a specific activator of p185erbB2. Science (1992) 4.17

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med (1995) 3.86

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75

WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73

Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73

Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature (1997) 3.64

Exact confidence interval of the SMR based on prevalence data. Int J Epidemiol (1994) 3.62

Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62

Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med (1998) 3.59

Proliferation of mutators in A cell population. J Bacteriol (1997) 3.55

Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am (1993) 3.55

Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA (2001) 3.55

Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49

Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46

Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42

Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology (2000) 3.42

Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40

MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35

Dietary effects on breast-cancer risk in Singapore. Lancet (1991) 3.32

The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res (2001) 3.30

Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27

A case of concomitant tuberculosis and sarcoidosis with mycobacterial DNA present in the sarcoid lesion. Chest (1998) 3.25

T-DNA insertional mutagenesis for functional genomics in rice. Plant J (2000) 3.25

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25

Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19

The H2O2 stimulon in Saccharomyces cerevisiae. J Biol Chem (1998) 3.19

Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16

Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med (1982) 3.08

A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05

Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03

A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02

Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00

Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc (2001) 2.98

Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood (2000) 2.95

Prediction of osteoporotic fractures by postural instability and bone density. BMJ (1993) 2.93

Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord (2003) 2.89

Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun (1995) 2.87

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86

Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86

Evidence-based disease management. JAMA (1997) 2.85

IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J (2001) 2.84

Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82

Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med (1993) 2.80

Human immunodeficiency virus infection in children. J Pediatr (1989) 2.80

Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73

Smaller inner ear sensory epithelia in Neurog 1 null mice are related to earlier hair cell cycle exit. Dev Dyn (2005) 2.71

Antibiotic-resistant group JK bacteria in hospitals. J Clin Microbiol (1981) 2.71

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res (2001) 2.68

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med (1988) 2.68

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol (1995) 2.66

Protein structure prediction by global optimization of a potential energy function. Proc Natl Acad Sci U S A (1999) 2.66

Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64

The Otto E. Aufranc Award: The role of labral lesions to development of early degenerative hip disease. Clin Orthop Relat Res (2001) 2.63

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61

Qualitative interview study of communication between parents and children about maternal breast cancer. BMJ (2000) 2.60

Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol (1999) 2.59

Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma. Hum Mol Genet (1998) 2.57

Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57

National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56

Mycoses caused by Candida lusitaniae. Rev Infect Dis (1988) 2.53

Forces exerted by locomoting cells. Semin Cell Biol (1994) 2.53